<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3F6336C-F927-4D82-BE24-8F7DE84D0B72"><gtr:id>D3F6336C-F927-4D82-BE24-8F7DE84D0B72</gtr:id><gtr:name>Birmingham Women's Hospital</gtr:name><gtr:address><gtr:line1>Third Floor (Academic Department)</gtr:line1><gtr:line2>Mindelsohn Way</gtr:line2><gtr:line4>Birmingham</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>B15 2TG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Centre for Cardiovascular Science</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3F6336C-F927-4D82-BE24-8F7DE84D0B72"><gtr:id>D3F6336C-F927-4D82-BE24-8F7DE84D0B72</gtr:id><gtr:name>Birmingham Women's Hospital</gtr:name><gtr:address><gtr:line1>Third Floor (Academic Department)</gtr:line1><gtr:line2>Mindelsohn Way</gtr:line2><gtr:line4>Birmingham</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>B15 2TG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C32E9430-021D-4676-85DE-838CD7B384A0"><gtr:id>C32E9430-021D-4676-85DE-838CD7B384A0</gtr:id><gtr:firstName>Asif</gtr:firstName><gtr:surname>Ahmed</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601295"><gtr:id>900044E6-EE87-44D4-B64A-7EE4805F3D90</gtr:id><gtr:title>Angiogenic Biomarkers as Predictive Tests for Early Onset Preeclampsia: A Population-Based Study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601295</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Preeclampsia (PE) is a systemic endothelial disease characterised by hypertension, proteinuria, exacerbated inflammation, dysregulated angiogenesis and can lead to end-organ failure. There are currently no reliable means to predict in early pregnancy who will go on to develop this condition, despite the many theories for the pathogenesis of PE. Also no definitive biomarker exists with the potential for risk stratification or delineation of the mechanism of action for potential therapeutic agents. The only effective treatment for PE resolution is delivery by Caesarean section. We and others have performed a variety of retrospective studies suggesting that specific angiogenic markers, placental growth factor (PlGF) and its antagonist soluble Flt-1 (sFlt1) and novel soluble endoglin (sEng) are promising screening tools capable of predicting PE prior to it?s clinical manifestations. These biomarkers are strongly rooted in the pathology of PE. It remains unknown, however, whether the test characteristics of these biomarkers are robust in a diverse European population and whether these tests perform well utilising high-throughput, highly sensitive assays. We hypothesise that a quantifiable increase in blood sEng and sFlt, and a decrease in blood and/or urine PlGF will antedate maternal clinical symptoms of early onset ( 32 weeks gestation) PE and differentiate it from late onset PE. To verify if changes in angiogenic and anti-angiogenic proteins can be used to accurately predict women at risk of developing early onset PE, we will test blood and urine samples collected longitudinally from over 40,000 pregnant women and assay for the blood sFlt1, and sEng and blood/urine PlGF levels screening for PE amongst asymptomatic women in early pregnancy at two time points (8-12 weeks gestation and 17-20 weeks gestation). To address these important aims, we have assembled a team with expertise in the biology of angiogenic markers and PE, clinical investigators with a track record of performing high-quality prospective studies in pregnancy, and medical device and immunoassay experts from industry. We believe this proposal will lead to the development of highly economical and robust testing strategies that will allow efficient assessment of potential therapeutic interventions, permit a targeted approach concentrating on women at the highest risk and also reduce NHS cost.</gtr:technicalSummary><gtr:fund><gtr:end>2012-05-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1222886</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham Women's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Khalid Khan - PREP Study</gtr:description><gtr:id>6A920C37-D873-4F06-ACF7-FDB2989BF9A1</gtr:id><gtr:impact>We have been awarded a HTA grant for the PREP study, 2010</gtr:impact><gtr:outcomeId>F307B67265F-1</gtr:outcomeId><gtr:piContribution>Development and validation of a Prediction model for Risk of complications in Early onset Pre eclampsia (PREP). This is based on the biomarker grant.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yale University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Irina Buhimschi - Angiogenic marker in preeclampsia</gtr:description><gtr:id>E4E1EE41-052F-4552-9351-A1AF6BFA215D</gtr:id><gtr:impact>Rosenberg VA, Buhimschi IA, Lockwood CJ, Paidas MJ, Dulay AT, Ramma W, Abdel-Razeq SS, Zhao G, Ahmad S, Ahmed A, Buhimschi CS. Heparin Elevates Circulating Soluble fms-Like Tyrosine Kinase-1 Immunoreactivity in Pregnant Women Receiving Anticoagulation Therapy. Circulation. 2011 Nov 14. [Epub ahead of print]

2. Edinburgh PhD - Wenda Ramma (one year in Yale)</gtr:impact><gtr:outcomeId>AmaFUAoU3SR-1</gtr:outcomeId><gtr:partnerContribution>One of my PhD student was able to go out to Yale and spend a year doing research on clinical samples which they had collected. This has resulted in a paper in Circulation and several other papers are in the pipeline.</gtr:partnerContribution><gtr:piContribution>We are one of the world's leading groups on angiogenic factors in pregnancy disorders and were able to generate the hypothesis which was tested by my student Dr Wenda Ramma (she obtained her PhD this summer). Thus we provided a student, supported her time at Yale and paid for the research consumables.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>PreDicT</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2D5BC2A1-AB98-427D-B28F-EA196847627E</gtr:id><gtr:impact>To establish a West Midland network of pregnancy biomarker centres.

Collaboration and subsequent grant funding from HTA.</gtr:impact><gtr:outcomeId>67B6C762EA0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>Health Technology Assessment programme</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>DD413723-EE76-454B-82B3-A941A4CE2B08</gtr:id><gtr:outcomeId>B62E3D70F2C0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The use of an agent for controlling vascular permeability within the cervix is disclosed for controlling cervical ripening. To hasten cervical ripening, the agent is one which increases vascular permeability and is selected from VEGF121, VEGF145, VEGF165, VEGF189, VEGF206, a smaller, active VEGF fragment, and placenta growth factor (PlGF). If cervical ripening is to be delayed, the agent is one which reduces vascular permeability, e.g. a VEGF receptor antagonist or antibody. The agents of the present invention can be used as a means of managing labor.</gtr:description><gtr:grantRef>G0601295</gtr:grantRef><gtr:id>038D4800-22F5-4D26-9D83-0132EE6F19D9</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>mmF1FoiarXb</gtr:outcomeId><gtr:patentId>US6946442 B2</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Method of hastening cervical ripening</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Established collaboration and obtained joint MRC Strategic funds in Translational Medicine. However, Abbott Diagnostics Inc. later pulled out due to financial downturn.</gtr:description><gtr:id>3CEA5B10-F941-4D73-BE63-D2C22DE82691</gtr:id><gtr:impact>Potentially it could lead to early diagnosis of preeclampsia which will allow StAmP trial output to provide a potential treatment for such patients.</gtr:impact><gtr:outcomeId>g39BFfJmaAw</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Abbott Diagnostics Inc.</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Generated a transgenic mouse to further study the novel pathways we have identified in preeclampsia</gtr:description><gtr:id>03DE6DE9-43A0-40ED-BF9F-2F4047455D08</gtr:id><gtr:impact>Not yet.</gtr:impact><gtr:outcomeId>Ui7Po2QUcMh</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Transgenic CSE null</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6C981F17-4501-4BBF-BEDC-E3D8BAB28159</gtr:id><gtr:title>New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications.</gtr:title><gtr:parentPublicationTitle>Thrombosis research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0049-3848</gtr:issn><gtr:outcomeId>UCy4ghMvbdb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47A9E5FF-DF73-4756-82C2-0D235B35E038</gtr:id><gtr:title>Nitric oxide-dependent bone marrow progenitor mobilization by carbon monoxide enhances endothelial repair after vascular injury.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba033bc7077768019119d506b1113191"><gtr:id>ba033bc7077768019119d506b1113191</gtr:id><gtr:otherNames>Wegiel B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_13962_22_20083679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCC12698-C003-4A45-B20F-F74E1B685F9F</gtr:id><gtr:title>The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df86efa291578c18d072c2f5017785c"><gtr:id>3df86efa291578c18d072c2f5017785c</gtr:id><gtr:otherNames>Cudmore MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_13962_22_22828632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00624FE0-EB22-4169-88A3-19C4F082D1D3</gtr:id><gtr:title>Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62f873f073f3e3dc32f6d6711448ce11"><gtr:id>62f873f073f3e3dc32f6d6711448ce11</gtr:id><gtr:otherNames>Al-Ani B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>pm_13962_22_20124108</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9FC4699-1008-41ED-BE7E-502FDDB46FC7</gtr:id><gtr:title>Is inflammation the cause of pre-eclampsia?</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9463437bd7e5cb2602492c65f758bf0f"><gtr:id>9463437bd7e5cb2602492c65f758bf0f</gtr:id><gtr:otherNames>Ramma W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>HvZstcutuw2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42ABE121-1C7C-4EF4-ADF6-3160A4064E52</gtr:id><gtr:title>Dysregulation of hydrogen sulfide producing enzyme cystathionine ?-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f5948b5a7f162e349b3184da5420ba0"><gtr:id>5f5948b5a7f162e349b3184da5420ba0</gtr:id><gtr:otherNames>Wang K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_13962_22_23704251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFF3ADA5-CF55-4A25-9486-98D208772E12</gtr:id><gtr:title>Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.</gtr:title><gtr:parentPublicationTitle>Journal of cellular and molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba203c9c1182ed4c8f88fae7dbd07a8b"><gtr:id>ba203c9c1182ed4c8f88fae7dbd07a8b</gtr:id><gtr:otherNames>Bergmann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1582-1838</gtr:issn><gtr:outcomeId>54F44732C96</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBAB2952-7A3E-4FF6-B7F3-A52962DF36C3</gtr:id><gtr:title>Hypoxia induces dilated cardiomyopathy in the chick embryo: mechanism, intervention, and long-term consequences.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2b1354b37c545a9b70b6f0a888e2576"><gtr:id>f2b1354b37c545a9b70b6f0a888e2576</gtr:id><gtr:otherNames>Tintu A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>8C1DBF93BAF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35E04F37-1609-4F03-A6E2-BC4029649851</gtr:id><gtr:title>Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df86efa291578c18d072c2f5017785c"><gtr:id>3df86efa291578c18d072c2f5017785c</gtr:id><gtr:otherNames>Cudmore MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>pm_13962_22_21411816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>164DBF63-C06F-43DC-BBF5-D694EDD50B05</gtr:id><gtr:title>Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5442c4521465e0.62586365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E16DE46E-80FB-432C-9B9B-51A379752158</gtr:id><gtr:title>Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad2b1e9bc82f6c5c24c365dd4a584a4f"><gtr:id>ad2b1e9bc82f6c5c24c365dd4a584a4f</gtr:id><gtr:otherNames>Cai J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55f98498457e7610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B78944A6-E2AF-49F0-BE92-A62A73F89541</gtr:id><gtr:title>Angiopoietin-1 induces migration of monocytes in a tie-2 and integrin-independent manner.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>NQf5nBw43RQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95693CDB-76CF-4A04-AD16-F007E777613B</gtr:id><gtr:title>Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba033bc7077768019119d506b1113191"><gtr:id>ba033bc7077768019119d506b1113191</gtr:id><gtr:otherNames>Wegiel B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_13962_22_24121491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3874497B-5246-42A4-A73A-B8D1183D6F97</gtr:id><gtr:title>Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta.</gtr:title><gtr:parentPublicationTitle>American journal of obstetrics and gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df86efa291578c18d072c2f5017785c"><gtr:id>3df86efa291578c18d072c2f5017785c</gtr:id><gtr:otherNames>Cudmore MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9378</gtr:issn><gtr:outcomeId>pm_13962_22_22197494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDFF569F-6A0B-4965-A826-2A8172FBC71E</gtr:id><gtr:title>Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08f22f61c9c7ba04d5600e1d249f775a"><gtr:id>08f22f61c9c7ba04d5600e1d249f775a</gtr:id><gtr:otherNames>Gould PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>pm_13962_22_20479331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2BFE389-20EC-48B8-830D-00FF40D9CD9C</gtr:id><gtr:title>Cardiac dysfunction and cell damage across clinical stages of severity in growth-restricted fetuses.</gtr:title><gtr:parentPublicationTitle>American journal of obstetrics and gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db04f47e38562b5929cb4cb7fd0366fe"><gtr:id>db04f47e38562b5929cb4cb7fd0366fe</gtr:id><gtr:otherNames>Crispi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9378</gtr:issn><gtr:outcomeId>761F845EB49</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E00BC21B-D835-4AEC-95E1-B44538B15A1A</gtr:id><gtr:title>Angiopoietin-1 promotes atherosclerosis by increasing the proportion of circulating Gr1+ monocytes.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d604ee1341cbc1b9b2547e5031d94928"><gtr:id>d604ee1341cbc1b9b2547e5031d94928</gtr:id><gtr:otherNames>Fujisawa T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>58991a458bb596.46742275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE2EB04C-C491-4A95-B1AA-73889EB563B4</gtr:id><gtr:title>Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be5026317591425446a36c3053435cbc"><gtr:id>be5026317591425446a36c3053435cbc</gtr:id><gtr:otherNames>Krueger J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn><gtr:outcomeId>th61K9tLifh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4656781-D43B-4D49-A4B4-CC4E4802D139</gtr:id><gtr:title>The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia.</gtr:title><gtr:parentPublicationTitle>Angiogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9463437bd7e5cb2602492c65f758bf0f"><gtr:id>9463437bd7e5cb2602492c65f758bf0f</gtr:id><gtr:otherNames>Ramma W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-6970</gtr:issn><gtr:outcomeId>pm_13962_22_22398973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D656310-2AC1-4514-8550-02C5EAC48941</gtr:id><gtr:title>Angiopoietin-2 confers Atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>AB14AC2A41C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBD1B919-A533-4EF9-8013-E35FD2E913E8</gtr:id><gtr:title>Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/815f2da051c44c835fee8fc5526e08a5"><gtr:id>815f2da051c44c835fee8fc5526e08a5</gtr:id><gtr:otherNames>Rana S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_13962_22_22261192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF6798B7-43E1-43BD-BB2C-493DCAC3E039</gtr:id><gtr:title>Multiple roles of angiopoietins in atherogenesis.</gtr:title><gtr:parentPublicationTitle>Current opinion in lipidology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0957-9672</gtr:issn><gtr:outcomeId>pm_13962_22_21881497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CB9C6DB-F4D9-4196-803B-5478982268F0</gtr:id><gtr:title>Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dce14b357c7844c03c8a3040606b07d8"><gtr:id>dce14b357c7844c03c8a3040606b07d8</gtr:id><gtr:otherNames>Rosenberg VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_540e14ee14ec90c0d</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601295</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>